Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JMP Securities analyst Roy Buchanan maintains CureVac (NASDAQ:CVAC) with a Market Outperform and lowers the price target fro...
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate ...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...
JMP Securities analyst Roy Buchanan reiterates CureVac (NASDAQ:CVAC) with a Market Outperform and maintains $18 price target.
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...
GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a ne...
CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative med...
